{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:51:55Z","timestamp":1790707915929,"version":"4.1.0"},"reference-count":23,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2013,6,18]],"date-time":"2013-06-18T00:00:00Z","timestamp":1371513600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0065763","type":"journal-article","created":{"date-parts":[[2013,6,18]],"date-time":"2013-06-18T21:08:24Z","timestamp":1371589704000},"page":"e65763","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":157,"title":["LY2405319, an Engineered FGF21 Variant, Improves the Metabolic Status of Diabetic Monkeys"],"prefix":"10.1371","volume":"8","author":[{"given":"Andrew C.","family":"Adams","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn A.","family":"Halstead","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara C.","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando R.","family":"Irizarry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer A.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon R.","family":"Myers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent L.","family":"Reynolds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly W.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor J.","family":"Wroblewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexei","family":"Kharitonenkov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2013,6,18]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.cmet.2011.10.012","article-title":"Metabolic disease drug discovery- \u201chitting the target\u201d is easier said than done","volume":"15","author":"DE Moller","year":"2012","journal-title":"Cell Metab"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.tips.2010.10.003","article-title":"Emerging therapies in the treatment of \u2018diabesity\u2019: beyond GLP-1","volume":"32","author":"G Tharakan","year":"2011","journal-title":"Trends Pharmacol Sci"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0167-4781(00)00067-1","article-title":"Identification of a novel FGF, FGF-21, preferentially expressed in the liver","volume":"1492","author":"T Nishimura","year":"2000","journal-title":"Biochim Biophys Acta"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"E1105","DOI":"10.1152\/ajpendo.00348.2009","article-title":"Acute glucose-lowering and insulin-sensitizing action of FGF21 in insulin-resistant mouse models\u2013association with liver and adipose tissue effects","volume":"297","author":"J Xu","year":"2009","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"254S","DOI":"10.3945\/ajcn.2009.28449B","article-title":"Fibroblast growth factor 21: from pharmacology to physiology","volume":"91","author":"SA Kliewer","year":"2010","journal-title":"Am J Clin Nutr"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.tem.2010.11.003","article-title":"FGF21 reloaded: challenges of a rapidly growing field","volume":"22","author":"A Kharitonenkov","year":"2011","journal-title":"Trends Endocrinol Metab"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1172\/JCI23606","article-title":"FGF-21 as a novel metabolic regulator","volume":"115","author":"A Kharitonenkov","year":"2005","journal-title":"J Clin Invest"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"e38438","DOI":"10.1371\/journal.pone.0038438","article-title":"Fundamentals of FGF19 &amp; FGF21 action in vitro and in vivo","volume":"7","author":"AC Adams","year":"2012","journal-title":"PLoS One"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"6018","DOI":"10.1210\/en.2008-0816","article-title":"Fibroblast growth factor 21 corrects obesity in mice","volume":"149","author":"T Coskun","year":"2008","journal-title":"Endocrinology"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"e40164","DOI":"10.1371\/journal.pone.0040164","article-title":"FGF21 Promotes Metabolic Homeostasis via White Adipose and Leptin in Mice","volume":"7","author":"MM Veniant","year":"2012","journal-title":"PLoS One"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"250","DOI":"10.2337\/db08-0392","article-title":"Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice","volume":"58","author":"J Xu","year":"2009","journal-title":"Diabetes"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"4192","DOI":"10.1210\/en.2012-1211","article-title":"Long-acting FGF21 has enhanced efficacy in diet-induced obese mice and in obese rhesus monkeys","volume":"153","author":"MM Veniant","year":"2012","journal-title":"Endocrinology"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"505","DOI":"10.2337\/db11-0838","article-title":"FGF21 analogs of sustained action enabled by orthogonal biosynthesis demonstrate enhanced antidiabetic pharmacology in rodents","volume":"61","author":"J Mu","year":"2012","journal-title":"Diabetes"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"e58575","DOI":"10.1371\/journal.pone.0058575","article-title":"Rational Design of a Fibroblast Growth Factor 21-Based Clinical Candidate, LY2405319","volume":"8","author":"A Kharitonenkov","year":"2013","journal-title":"PLoS One"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1210\/en.2006-1168","article-title":"The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21","volume":"148","author":"A Kharitonenkov","year":"2007","journal-title":"Endocrinology"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/978-1-62703-068-7_11","article-title":"Investigation and treatment of type 2 diabetes in nonhuman primates","volume":"933","author":"BC Hansen","year":"2012","journal-title":"Methods Mol Biol"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Adams AC, Yang C, Coskun T, Cheng CC, Gimeno RE, <etal>et al<\/etal>.. (2012) The breadth of FGF21s metabolic actions are governed by FGFR1 in adipose tissue Molecular Metabolism 1.","DOI":"10.1016\/j.molmet.2012.08.007"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Adams AC, Cheng CC, Coskun T, Kharitonenkov A (2012) FGF21 requires \u03b2klotho to act in vivo. PLoS One.","DOI":"10.1371\/journal.pone.0049977"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Murphy M, Samms R, Warner A, Bolborea M, Barrett P, <etal>et al<\/etal>.. (2012) Increased responses to the actions of fibroblast growth factor 21 on energy balance and body weight in a seasonal model of adiposity. J Neuroendocrinol.","DOI":"10.1111\/j.1365-2826.2012.02383.x"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.cmet.2012.08.002","article-title":"betaKlotho is required for fibroblast growth factor 21 effects on growth and metabolism","volume":"16","author":"X Ding","year":"2012","journal-title":"Cell Metab"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1007\/s00125-012-2598-x","article-title":"Adiponectin: mechanistic insights and clinical implications","volume":"55","author":"AT Turer","year":"2012","journal-title":"Diabetologia"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.cmet.2013.04.005","article-title":"Adiponectin Mediates the Metabolic Effects of FGF21 on Glucose Homeostasis and Insulin Sensitivity in Mice","volume":"17","author":"Z Lin","year":"2013","journal-title":"Cell Metab"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.cmet.2013.03.019","article-title":"An FGF21-Adiponectin-Ceramide Axis Controls Energy Expenditure and Insulin Action in Mice","volume":"17","author":"WL Holland","year":"2013","journal-title":"Cell Metab"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0065763","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,2]],"date-time":"2023-07-02T12:48:36Z","timestamp":1688302116000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0065763"}},"subtitle":[],"editor":[{"given":"Yu","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2013,6,18]]},"references-count":23,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2013,6,18]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0065763","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,6,18]]}}}